Greenstone Llc Initiates Nationwide Class II Recall of Methylprednisolone Tablets Due to Critical Labeling Error
Greenstone Llc has initiated a voluntary Class II nationwide recall (D-0299-2026) for 3,456 cartons of methylprednisolone tablets, USP Dosepak, 4 mg. The recall stems from an incorrect orientation of the blister foil, leading to erroneous dosing instructions. This packaging error, affecting Lot # LG7675, Exp. Date Nov 2026, poses a risk of incorrect medication administration, necessitating immediate action from procurement and regulatory teams to assess supply chain integrity and patient safety protocols.
What the FDA Found: Critical Labeling Error for Methylprednisolone Dosepak
Greenstone Llc, based in Peapack, NJ, United States, has initiated a voluntary Class II recall, identified as D-0299-2026, for specific lots of its methylprednisolone tablets, USP Dosepak, 4 mg. The fundamental issue identified by the FDA pertains to a critical labeling error: an incorrect orientation of the blister foil applied to the blister cavities. This misorientation directly results in incorrect dosing information when patients follow the directions printed on the foil. For procurement directors, this incident underscores the paramount importance of stringent quality control not only for active pharmaceutical ingredients (APIs) but also for finished product packaging and labeling. A seemingly minor packaging defect can lead to significant patient safety risks and substantial commercial repercussions. The affected product is methylprednisolone tablets, USP Dosepak, 4 mg, 1 Blister Card per Carton containing 21 Tablets, Rx only, with NDC 59762-4440-2. The recall specifically targets Lot # LG7675, which carries an expiration date of November 2026. This recall, initiated on January 15, 2026, and reported on February 4, 2026, remains ongoing, indicating continued efforts to remove the compromised product from the market. Supply chain VPs must recognize that such errors can disrupt distribution channels nationwide within the United States, impacting patient access and requiring costly reverse logistics.
Product Details and Immediate Supply Chain Impact
The recalled product, methylprednisolone tablets, is a corticosteroid (NUI: N0000175576, N0000175450) commonly prescribed for its anti-inflammatory and immunosuppressive effects. Distributed by Greenstone Llc, the product is manufactured by Mylan Pharmaceuticals Inc. (NDA011153), highlighting a critical inter-company dependency in the supply chain. The specific dosage form, a 4 mg Dosepak containing 21 tablets, is designed for a precise tapering regimen, making accurate dosing instructions on the blister foil absolutely essential for patient compliance and therapeutic efficacy. The recall involves a significant quantity of 3,456 cartons, distributed nationwide across the United States. For business development executives, this event signals potential market disruption for this specific product presentation and could influence prescriber confidence in the Dosepak format if not swiftly and effectively remediated. Procurement teams must immediately assess their inventory and distribution networks for the affected Lot # LG7675 to prevent further dispensing of mislabeled product. Furthermore, this incident necessitates a review of supplier agreements with both distributors like Greenstone Llc and manufacturers such as Mylan Pharmaceuticals Inc., focusing on quality assurance clauses related to packaging and labeling integrity. The recall’s Class II classification indicates that exposure to the mislabeled product could cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote.
Regulatory Classification and Market Implications for Greenstone Llc
The FDA's classification of this event as a Class II recall signifies that while the health consequences are not immediately life-threatening, they are potentially temporary or medically reversible. More critically, there is a remote probability of serious adverse health consequences if patients follow the incorrect dosing instructions. This classification, coupled with the voluntary, firm-initiated nature of the recall by Greenstone Llc, demonstrates the company's recognition of the potential patient safety risks. For regulatory affairs heads, this incident underscores the critical importance of robust quality management systems that extend beyond manufacturing to packaging and labeling. A failure in this area can lead to patient harm, product liability issues, and significant reputational damage. The ongoing status of recall D-0299-2026 means that Greenstone Llc is actively working to remove the product from the market and address the root cause of the labeling error. This situation may prompt enhanced scrutiny from the FDA on Greenstone Llc's overall quality systems and those of its manufacturing partner, Mylan Pharmaceuticals Inc., particularly concerning packaging line controls and final product release procedures. Business development executives should monitor the market response and potential shifts in prescribing patterns for methylprednisolone, as prescribers may opt for alternative formulations or suppliers to mitigate perceived risks.
Broader Industry Trends in Pharmaceutical Recalls and Quality Assurance
The recall of methylprednisolone tablets by Greenstone Llc due to a packaging error is not an isolated incident within the broader pharmaceutical landscape. Recent parallel events highlight a persistent challenge in maintaining stringent quality control across various stages of drug production and packaging. For instance, Essential Wellness Pharma faced a Class II recall for its Progesterone Injection in June 2026 due to sterility assurance failures, a critical issue that can lead to severe patient outcomes. Similarly, Spectra Medical Devices' Lidocaine HCl Injection encountered a high-severity Class II recall in June 2026, also citing sterility assurance deficiencies. These events, alongside Guardian Drug Co. Inc.'s nationwide Class II recalls for Calcium Carbonate Antacids and HyVee Antacid in June 2026 due to metallic contamination, underscore a systemic vulnerability in manufacturing and quality oversight. Procurement directors and supply chain VPs must recognize that these diverse recall triggers—ranging from packaging errors to sterility and contamination issues—mandate a holistic approach to supplier qualification and ongoing monitoring. Relying solely on API quality is insufficient; comprehensive audits must extend to finished product manufacturing, packaging lines, and environmental controls. This trend suggests that companies across the chemical and life sciences industry need to reinforce their internal and external quality assurance frameworks to mitigate risks and maintain patient trust.
Remediation Expectations and Future Compliance Outlook for Greenstone Llc
As a voluntary Class II recall, Greenstone Llc is expected to undertake a comprehensive remediation plan to address the root cause of the blister foil misorientation and prevent recurrence. This typically involves a thorough investigation into the manufacturing and packaging processes at Mylan Pharmaceuticals Inc., followed by the implementation of robust Corrective and Preventive Actions (CAPA). For regulatory affairs heads, monitoring Greenstone Llc's response and ensuring the adequacy of their CAPA plan is crucial, as the FDA will likely scrutinize these actions during any future inspections. The company will need to demonstrate that its quality management system can effectively identify, investigate, and correct such critical labeling errors. Given the nationwide distribution, Greenstone Llc must also ensure effective communication with all affected customers, including pharmacies, wholesalers, and healthcare providers, to facilitate the return of the recalled Lot # LG7675. Procurement teams sourcing other products from Greenstone Llc or Mylan Pharmaceuticals Inc. should conduct an immediate risk assessment, potentially initiating enhanced supplier audits or requesting detailed documentation of quality control improvements. Failure to adequately address this recall could lead to further regulatory actions, including potential Warning Letters or even product seizures, impacting future market access and commercial viability for both the distributor and the manufacturer. The ongoing status of the recall indicates that these remediation efforts are currently underway.